Sulbactam/ETX 2514

Drug Profile

Sulbactam/ETX 2514

Alternative Names: ETX 2514/Sulbactam; ETX 2514SUL

Latest Information Update: 01 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Entasis Therapeutics
  • Class Anti-infectives; Antibacterials
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acinetobacter infections

Most Recent Events

  • 01 Jun 2017 Entasis Therapeutics completes a phase I trial in Acinetobacter infections (In volunteers) in Australia (IV) (NCT02971423)
  • 22 Apr 2017 Antimicrobial data from preclinical trials in Acinetobacter infections presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
  • 28 Oct 2016 Preclinical trials in Acinetobacter infections in USA before October 2016 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top